Table S4 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors

Authors: Jaime R. Merchan, Manish R. Patel, Timothy P. Cripe et al.
Publication:
Published: Unknown date
Source: Crossref
Back to Search View Original Cite This Article

Abstract

<jats:p>&lt;p&gt;Part 1 baseline demographics&lt;/p&gt;</jats:p>

Keywords

ppart baseline demographicsp

Related Articles

‘It is my life don’t take that choice from me’: Autistic young adults’ experiences, preferences and needs regarding autistic peer support

Tohid Zarei, Caelan Farr et al. - Unknown

Read More
Laminin-511 protects pancreatic β-cells from cytokine-induced death through integrin-mediated pro-survival signaling and modulation of protein kinase C δ

Christine El-Dirani, Meghana Hosahalli Shivananda Murthy et al. - Unknown

Read More
From digitalization to resilience: How digital transformation and climate readiness shape bank stability in Indonesia

Trisninik Ratih Wulandari, Bimo Saktiawan et al. - Unknown

Read More
figure S6 from RETRACTED: A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity

Mario I. Vega, Yijiang Shi et al. - Unknown

Read More
Table S11 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors

Jaime R. Merchan, Manish R. Patel et al. - Unknown

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0